Cogent Biosciences, Inc. (NASDAQ:COGT – Free Report) – Research analysts at HC Wainwright issued their Q1 2027 earnings estimates for Cogent Biosciences in a note issued to investors on Wednesday, August 19th. HC Wainwright analyst R. Burns expects that the technology company will post earnings per share of ($0.50) for the quarter. HC Wainwright has a “Buy” rating and a $55.00 price target on the stock. The consensus estimate for Cogent Biosciences’ current full-year earnings is ($2.21) per share. HC Wainwright also issued estimates for Cogent Biosciences’ Q2 2027 earnings at ($0.38) EPS, Q3 2027 earnings at ($0.26) EPS, Q4 2027 earnings at ($0.15) EPS and FY2027 earnings at ($1.28) EPS.
Cogent Biosciences (NASDAQ:COGT – Get Free Report) last issued its quarterly earnings data on Monday, August 10th. The technology company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.03.
Read Our Latest Stock Analysis on COGT
Cogent Biosciences Trading Down 1.5%
NASDAQ:COGT opened at $36.85 on Thursday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 13.57 and a current ratio of 13.57. The firm has a market cap of $6.39 billion, a P/E ratio of -17.06 and a beta of 0.38. Cogent Biosciences has a one year low of $11.53 and a one year high of $43.73. The firm has a 50-day simple moving average of $38.36 and a 200-day simple moving average of $36.63.
Institutional Trading of Cogent Biosciences
Several institutional investors have recently added to or reduced their stakes in COGT. AQR Capital Management LLC lifted its holdings in Cogent Biosciences by 482.6% during the 1st quarter. AQR Capital Management LLC now owns 160,767 shares of the technology company’s stock worth $963,000 after buying an additional 133,174 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Cogent Biosciences by 6.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 62,275 shares of the technology company’s stock worth $377,000 after buying an additional 3,693 shares during the period. Goldman Sachs Group Inc. increased its stake in Cogent Biosciences by 14.3% in the first quarter. Goldman Sachs Group Inc. now owns 988,962 shares of the technology company’s stock valued at $5,924,000 after purchasing an additional 124,069 shares during the period. Jane Street Group LLC raised its stake in shares of Cogent Biosciences by 66.2% during the first quarter. Jane Street Group LLC now owns 123,822 shares of the technology company’s stock worth $742,000 after purchasing an additional 49,338 shares during the last quarter. Finally, Strs Ohio purchased a new position in Cogent Biosciences during the first quarter worth about $36,000.
Cogent Biosciences Company Profile
Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.
The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.
Featured Stories
- Five stocks we like better than Cogent Biosciences
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for Cogent Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogent Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
